Basic characteristics and treatment regimens in people with type 1 diabetes in the international diabetes management practices study (IDMPS)

FERREIRA S; RAMACHANDRAN A; ASCHNER P; CHAN J; HANCU N; BAIK SH; ILKOVA H; TWIGG S; GAGLIARDINO JJ

Dinamarca

Congreso; 42nd Annual Meeting of the European Association for the Study of Diabetes; 2006

European Association for the Study of Diabetes

Background and Aims: This multinational observational study is being performed to gather data that reflect current practices in the management of people with diabetes in different areas of the world and to evaluate compliance with international guidelines. Materials and Methods: Data are being collected from type 1 diabetic patients (Q18 years) in 1-year cycles (a 2-week cross-sectional period followed by a 9-month longitudinal period) for 5 years. Results: Data from the first cross-sectional period are available from 1327 people (51% men) in 11 countries in Eastern Europe, Asia, and Latin America. The mean age was 36T13 years, mean BMI 23T4 kg/m2 (for both men and women) and mean disease duration 11 years. Mean HbA1c was 8.2T1.96% and 27% of people had an HbA1c <7%. Mean FBG (laboratory) was 161T75 mg/dL. Mean systolic/diastolic blood pressure was 122/75 mmHg. Target treatment levels were achieved for LDL (<100 mg/dL) in 41% of people, for HDL (>40 g/dL) in 81%, and for triglycerides (<150 mg/dL) in 72% of people. A basal+prandial insulin regimen was used by 51% of people with an average daily dose of 52 IU insulin and a mean HbA1c of 8.1%. Premixed insulin was used by 27% of people with an average dose of 38 IU insulin and a mean HbA1c of 8.5%. Only 9% of people were using a basal insulin alone (average dose 31 IU insulin and mean HbA1c 8.5%) and 4% a prandial insulin alone (average dose 29 IU insulin and mean HbA1c 7.6%). Conclusion: As can be seen, despite the findings of the DCCT and the recommendations of the ADA, the majority of people recruited have not achieved the recommended treatment goals for HbA1c and FBG. It is thus apparent that more efficient guidance and education be made available to improve treatment outcomes in type 1 diabetic patients world wide.